Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q1 2024 · 10-Q
Revenue—
Net Income$1.54M$1.54MN/M vs Q1 2023 EPS Diluted$0.04$0.04N/M vs Q1 2023 Operating Income-$2,962,000N/M Operating Cash Flow-$1,476,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,478,000N/M ended Mar 31, 2024 · filed May 9, 2024 · 39 d after period end